東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Development of Novel Cancer Treatmen...

Pan, Roy David.

FindBook

Google Book

Amazon

博客來

Development of Novel Cancer Treatments Targeting Pyrimidine Nucleotide Biosynthesis and the Synthesis of Tool Compounds for Enhanced Profiling of Oxidative Post-translational Modifications.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Development of Novel Cancer Treatments Targeting Pyrimidine Nucleotide Biosynthesis and the Synthesis of Tool Compounds for Enhanced Profiling of Oxidative Post-translational Modifications./
作者:	Pan, Roy David.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
面頁冊數:	189 p.
附註:	Source: Dissertations Abstracts International, Volume: 83-01, Section: B.
Contained By:	Dissertations Abstracts International83-01B.
標題:	Chemistry. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28546695
ISBN:	9798516925566

Development of Novel Cancer Treatments Targeting Pyrimidine Nucleotide Biosynthesis and the Synthesis of Tool Compounds for Enhanced Profiling of Oxidative Post-translational Modifications.
Pan, Roy David.

Development of Novel Cancer Treatments Targeting Pyrimidine Nucleotide Biosynthesis and the Synthesis of Tool Compounds for Enhanced Profiling of Oxidative Post-translational Modifications. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 189 p.

Source: Dissertations Abstracts International, Volume: 83-01, Section: B.

Thesis (Ph.D.)--University of California, Los Angeles, 2021.

This item must not be sold to any third party vendors.

This dissertation details the chemistry work that has been done to support the Radu lab's cancer research efforts. Although cancer research is typically performed via cell cultures, tissue cultures, mice studies, etc., there are many aspects that require specialized chemistry to accomplish. What is sometimes overlooked or quickly summarized is the tedious chemistry groundwork that may lead to the invention of a successful drug or tool compound, enabling interesting biology to be studied or observed. Even though publications generally focus on successful final outcomes, failed cases can provide important lessons going forward. For example, sometimes new compounds no longer target the desired protein, but can still treat cancer or elicit intriguing biological outcomes. Whether or not the projects detailed in this dissertation were successful is subjective and may not be determined in a short period of time. Nonetheless, the accurate documentation of this work hopefully may provide the opportunity for other scientists to learn from and build upon. This dissertation outlines the results of three independent projects all revolving around the development of novel cancer therapies. In Chapter One, new inhibitors of deoxycytidine kinase that were designed to improve upon drug-like properties such as solubility or ease of synthesis will be introduced. The new compounds will be compared to the clinically-viable lead, (R)-DI-87, and assessed in terms of potency, solubility, and ease of synthesis. At the end of Chapter One, how a dCK inhibitor possessing an amine handle, NMc-77, was used to construct potential deoxycytidine kinase degraders will also be described. In Chapter Two, HCT13, a thiosemicarbazone derivative, was made initially to improve upon Triapine's ribonucleotide reductase-inhibiting activity. Surprisingly, small structural changes abolished the compound's activity against ribonucleotide reductase, yet HCT13 remained a potent and effective drug against aggressive leukemia in mouse models. Lastly, Chapter Three will detail efforts to synthesize cysteine labeling compounds that can enable high-throughput studies of cysteine oxidative post-translational modifications. These tool compounds may help scientists gain more insight into various treatment efficacies and resistance mechanisms by elucidating changes in cysteine-mediated redox signaling.

ISBN: 9798516925566Subjects--Topical Terms:

516420
Chemistry.
Subjects--Index Terms:

Deoxycytidine kinase

Development of Novel Cancer Treatments Targeting Pyrimidine Nucleotide Biosynthesis and the Synthesis of Tool Compounds for Enhanced Profiling of Oxidative Post-translational Modifications.
LDR:03695nmm a2200373 4500 001 2281680
005 20210920103616.5
008 220723s2021 ||||||||||||||||| ||eng d
020 $a 9798516925566
035 $a (MiAaPQ)AAI28546695
035 $a AAI28546695
040 $a MiAaPQ $c MiAaPQ
100 1 $a Pan, Roy David. $3 3560364
245 1 0 $a Development of Novel Cancer Treatments Targeting Pyrimidine Nucleotide Biosynthesis and the Synthesis of Tool Compounds for Enhanced Profiling of Oxidative Post-translational Modifications.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 189 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-01, Section: B.
500 $a Advisor: Radu, Caius G.;Jung, Michael E.
502 $a Thesis (Ph.D.)--University of California, Los Angeles, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a This dissertation details the chemistry work that has been done to support the Radu lab's cancer research efforts. Although cancer research is typically performed via cell cultures, tissue cultures, mice studies, etc., there are many aspects that require specialized chemistry to accomplish. What is sometimes overlooked or quickly summarized is the tedious chemistry groundwork that may lead to the invention of a successful drug or tool compound, enabling interesting biology to be studied or observed. Even though publications generally focus on successful final outcomes, failed cases can provide important lessons going forward. For example, sometimes new compounds no longer target the desired protein, but can still treat cancer or elicit intriguing biological outcomes. Whether or not the projects detailed in this dissertation were successful is subjective and may not be determined in a short period of time. Nonetheless, the accurate documentation of this work hopefully may provide the opportunity for other scientists to learn from and build upon. This dissertation outlines the results of three independent projects all revolving around the development of novel cancer therapies. In Chapter One, new inhibitors of deoxycytidine kinase that were designed to improve upon drug-like properties such as solubility or ease of synthesis will be introduced. The new compounds will be compared to the clinically-viable lead, (R)-DI-87, and assessed in terms of potency, solubility, and ease of synthesis. At the end of Chapter One, how a dCK inhibitor possessing an amine handle, NMc-77, was used to construct potential deoxycytidine kinase degraders will also be described. In Chapter Two, HCT13, a thiosemicarbazone derivative, was made initially to improve upon Triapine's ribonucleotide reductase-inhibiting activity. Surprisingly, small structural changes abolished the compound's activity against ribonucleotide reductase, yet HCT13 remained a potent and effective drug against aggressive leukemia in mouse models. Lastly, Chapter Three will detail efforts to synthesize cysteine labeling compounds that can enable high-throughput studies of cysteine oxidative post-translational modifications. These tool compounds may help scientists gain more insight into various treatment efficacies and resistance mechanisms by elucidating changes in cysteine-mediated redox signaling.
590 $a School code: 0031.
650 4 $a Chemistry. $3 516420
650 4 $a Pharmacology. $3 634543
653 $a Deoxycytidine kinase
653 $a Oxidized cysteine
653 $a PROTAC
653 $a Pyrimidine nucleotide
653 $a Redox
653 $a Thiosemicarbazone
690 $a 0485
690 $a 0419
710 2 $a University of California, Los Angeles. $b Chemistry 0153. $3 2096181
773 0 $t Dissertations Abstracts International $g 83-01B.
790 $a 0031
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28546695